TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

David B Rosen ,Kristin Laura Abel,Anne Månsson Kvarnhammar,Philipp Glock,Valentino Konjik,Thomas Wegge,Yvonne Hehn,Janne Damm Olling,Laura Viet,Ana Bernhard,Diana Reich,Dhruv Thakar,Stefan Heinig,Frank Faltinger,Steffen Killian,Kathy Bang,Josefine Runz,Burkhardt Laufer,Karan Uppal,Meike Schnabel,Thomas Kurpiers,Thomas A Knappe ,Luis A Zúñiga ,Simran S Sabharwal ,Kennett Sprogoe ,Stina Mui Singel ,Jens-Jakob Karlsson ,Vibeke Breinholt ,Yu‐Chi Lee ,Kristian Kjærgaard ,Mohammad Tabrizi,Joachim Zettler,Enping Hong,Mathias Krusch,Juha Punnonen

doi:10.1136/jitc-2022-004991

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

David B Rosen , Kristin Laura Abel + Show 33 more

Open Access

https://doi.org/10.1136/jitc-2022-004991

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Jul 1, 2022
Citations: 16	License type: open-access

Affiliation: Ascendis Pharma (Denmark)

#Natural Killer Cells #Vascular Leak Syndrome + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundRecombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ+ natural killer (NK)...

Full Text